Kenneth Galbraith
InvestorExecutive Partner of Syncona Investment Management Limited at Syncona
Cambridge, England, United Kingdom
About
Kenneth Galbraith is an Executive Partner of Syncona Investment Management Limited, and in November 2024 was announced as joining the SIML Board and taking on the role of Chair (effective after regulatory approval). He has around 35 years of experience in biotechnology and venture capital, having served as CEO, CFO, Executive Chair, director, investor and advisor at both private and NASDAQ-listed companies across North America. He began his career in 1987 as CFO of QLT and currently serves as Chair and CEO of Zymeworks.
Invests in
BiotechMedical Devices
Experience
- SYNCONA INVESTMENT MANAGEMENT LIMITEDChaircurrent2025 — presentLondon Area, United Kingdom
- ZOMPDirectorcurrent2023 — presentCambridge, England, United Kingdom
- Zymeworks Inc.Chair and Chief Executive Officercurrent2022 — presentVancouver, British Columbia, Canada
- Syncona LimitedExecutive Partner2023 — 2025
- Kalium HealthExecutive Chair2021 — 2024Cambridge, England, United Kingdom
- Profound Medical Inc.Corporate Director2017 — 2023Mississauga, Ontario, Canada
- Syncona LimitedExecutive In Residence2021 — 2022London, England, United Kingdom
- Five Corners CapitalManaging Director2021 — 2022Cambridge, England, United Kingdom
- MacroGenics, Inc.Corporate Director2008 — 2022Rockville, Maryland, United States
- Liminal BioSciencesAdvisor2020 — 2021
- Liminal BioSciencesChief Executive Officer2019 — 2020Sawston, Cambridgeshire, United Kingdom
- PrometicChief Executive Officer2019Laval, Quebec, Canada
- Fairhaven Pharmaceuticals Inc.Chief Executive Officer2017 — 2019Canada
- Prometic BioProduction & BioTherapeuticsCorporate Director2016 — 2019Laval, Quebec, Canada
- Five Corners Capital Inc.Managing Director2013 — 2019White Rock
- Genesys Capital PartnersVenture Partner2013 — 2019Toronto, Ontario, Canada
- NeurAxon IncCorporate Director2008 — 2015Toronto, Ontario, Canada
- Tekmira PharmaceuticalsCorporate Director2010 — 2014Burnaby, British Columbia, Canada
- Genome British ColumbiaBoard Member2008 — 2014Vancouver, British Columbia, Canada
- TRACON PharmaceuticalsChairman Of The Board2011 — 2014San Diego, California, United States
- Genome BCCorporate Director2008 — 2014Vancouver, British Columbia, Canada
Skills & more
Executive Management3Start-ups16Strategy6Capital RaisingVenture ManagementBoard of DirectorsBiotechnology14Drug Development6Business Development3
From Kenneth's professional profile.
Investments
Board seats
Kalium HealthZOMPZymeworks
Per the firm's website.
Colleagues at Syncona
Frequently asked questions
- Who is Kenneth Galbraith?
- Kenneth Galbraith is an Executive Partner of Syncona Investment Management Limited, and in November 2024 was announced as joining the SIML Board and taking on the role of Chair (effective after regulatory approval). He has around 35 years of experience in biotechnology and venture capital, having served as CEO, CFO, Executive Chair, director, investor and advisor at both private and NASDAQ-listed companies across North America. He began his career in 1987 as CFO of QLT and currently serves as Chair and CEO of Zymeworks.
- Where does Kenneth Galbraith work?
- Kenneth Galbraith is Executive Partner of Syncona Investment Management Limited at Syncona.
- What does Kenneth Galbraith invest in?
- Kenneth Galbraith invests in Biotech, Medical Devices.
- What boards does Kenneth Galbraith sit on?
- Kenneth Galbraith holds tracked board seats at Kalium Health, ZOMP, Zymeworks.
- Where did Kenneth Galbraith go to school?
- Kenneth Galbraith studied at University of BC (B.Comm ( Honours)).
